Supernus Pharmaceuticals Inc (SUPN) 13.76 $SUPN
First Week of SUPN December 18th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:34AM CDT
Investors in Supernus Pharmaceuticals Inc saw new options begin trading this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until...
SUPN: 13.76 (-0.18)
Supernus to Host First Quarter 2015 Earnings Conference Call
GlobeNewswire - Tue Apr 21, 4:00PM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2015 after 5:00 PM ET on Tuesday, May 5, 2015.
SUPN: 13.76 (-0.18)
Supernus wins sixth patent protecting the antiepileptic drugTrokendi XR in the US
M2 - Fri Apr 03, 3:06AM CDT
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) revealed on Thursday the receipt of the sixth patent from the US Patent and Trademark Office (USPTO) covering its novel once-daily extended-release topiramate product, Trokendi XR, for the treatment of epilepsy.
SUPN: 13.76 (-0.18)
Supernus Announces Issuance of Sixth U.S. Patent Protecting Trokendi XR(R)
GlobeNewswire - Thu Apr 02, 3:30PM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on March 31, 2015 of a sixth patent (number 8,992,989) by the United States Patent and Trademark Office (USPTO) covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.
SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:32AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
AKRX: 55.24 (-0.68), SUPN: 13.76 (-0.18)
Georges Gemayel, Ph.D., Joins Supernus Board of Directors
GlobeNewswire - Mon Mar 23, 4:12PM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Georges Gemayel, Ph.D., a veteran executive with extensive experience in the pharmaceutical industry, will join the company's board of directors.
SUPN: 13.76 (-0.18)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 18.52 (-0.03), MDT: 77.61 (-0.89), RARE: 69.65 (+0.75), PFE: 35.27 (-0.09), SUPN: 13.76 (-0.18), NRX: 8.26 (-0.08), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), SVA: 5.10 (unch), BLRX: 2.10 (-0.02), AMPH: 15.25 (-0.04), CHRS: 23.52 (-0.88), JNJ: 101.08 (+0.62), GNVC: 2.82 (+0.01), CYCC: 0.96 (+0.02), AZN: 71.79 (-1.34), DPRX: 12.85 (+0.27), TEVA: 64.41 (+1.16), NBY: 0.63 (unch)
Nasdaq stocks posting largest volume increases
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), ISSI: 18.26 (-0.06), BONT: 7.35 (+0.19), ZGNX: 1.54 (-0.11), SUPN: 13.76 (-0.18), TISA: 3.36 (-0.03), VRA: 13.94 (-0.02), IROQ: 16.64 (+0.14), FCCY: 11.68 (+0.22), REPH: 11.88 (+1.04)
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SUPN: 13.76 (-0.18), NMRX: 11.98 (+0.09), EPZM: 20.21 (+0.16), EGRX: 59.30 (-1.62), SLTC: 5.94 (+0.11), ISSI: 18.26 (-0.06), BONT: 7.35 (+0.19), CONN: 30.85 (+0.15), INGN: 37.13 (+0.11), TWOU: 27.86 (-0.91), SCLN: 8.96 (-0.13), CBMG: 29.51 (-1.85)
Citigroup and Intel are big market movers
AP - Thu Mar 12, 4:03PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
ACAD: 38.36 (-0.54), BONT: 7.35 (+0.19), ZGNX: 1.54 (-0.11), SUPN: 13.76 (-0.18), SLXP: 172.96 (+0.15), VRA: 13.94 (-0.02), INTC: 32.08 (-0.27)
Supernus Gains on Solid Q4 Earnings, Encouraging Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 2:46PM CDT
Shares of Supernus Pharmaceuticals, Inc. (SUPN) gained 10.8% after the company reported solid results for the fourth quarter of 2014.
MNK: 122.01 (-2.84), IPXL: 49.55 (-0.53), ACT: 295.41 (-2.95), SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals, Inc. (SUPN) Rises: Stock Up 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 8:32AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
AKRX: 55.24 (-0.68), SUPN: 13.76 (-0.18)
Why Supernus Pharmaceuticals, Inc. Stock Spiked
George Budwell, The Motley Fool - Motley Fool - Wed Mar 11, 2:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the specialty drugmaker Supernus...
SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals (SUPN) Stock Is Up Today on Earnings Beat
at The Street - Wed Mar 11, 10:58AM CDT
Supernus Pharmaceuticals (SUPN) is gaining Wednesday after beating analysts' estimates for earnings and revenue in the fourth quarter
SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals' (SUPN) CEO Jack Khattar on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 11, 10:22AM CDT
SUPN: 13.76 (-0.18)
Supernus beats Street 4Q forecasts
Automated Insights - Tue Mar 10, 5:02PM CDT
ROCKVILLE, Md. (AP) _ Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported fourth-quarter net income of $4.4 million, after reporting a loss in the same period a year earlier.
SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals beats by $0.21, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 4:06PM CDT
SUPN: 13.76 (-0.18)
Supernus Announces Fourth Quarter and Full Year 2014 Results
GlobeNewswire - Tue Mar 10, 4:00PM CDT
-- Cash flow positive for the fourth quarter, $5.9 million, and for the full year, $3.2 million.
SUPN: 13.76 (-0.18)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 4:35PM CDT
FCEL: 1.30 (-0.01), SINA: 38.54 (+1.19), NCS: 16.35 (+0.18), ZGNX: 1.54 (-0.11), EOX: 0.61 (-0.02), SUPN: 13.76 (-0.18), HABT: 34.51 (+0.56), ONTY: 1.74 (-0.05), HRZN: 14.30 (+0.06), HTHT: 23.40 (+0.30), SURG: 5.24 (+0.02), WB: 17.20 (+1.31), TCRD: 12.29 (-0.06), MPO: 1.09 (-0.07), PAY: 35.64 (-0.48)
First Week of SUPN December 18th Options Trading
StockOptionsChannel.com - Wed Apr 22, 10:34AM CDT
Investors in Supernus Pharmaceuticals Inc saw new options begin trading this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until...
SUPN: 13.76 (-0.18)
Supernus to Host First Quarter 2015 Earnings Conference Call
GlobeNewswire - Tue Apr 21, 4:00PM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the first quarter of 2015 after 5:00 PM ET on Tuesday, May 5, 2015.
SUPN: 13.76 (-0.18)
Supernus wins sixth patent protecting the antiepileptic drugTrokendi XR in the US
M2 - Fri Apr 03, 3:06AM CDT
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) revealed on Thursday the receipt of the sixth patent from the US Patent and Trademark Office (USPTO) covering its novel once-daily extended-release topiramate product, Trokendi XR, for the treatment of epilepsy.
SUPN: 13.76 (-0.18)
Supernus Announces Issuance of Sixth U.S. Patent Protecting Trokendi XR(R)
GlobeNewswire - Thu Apr 02, 3:30PM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance on March 31, 2015 of a sixth patent (number 8,992,989) by the United States Patent and Trademark Office (USPTO) covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.
SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 8:32AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
AKRX: 55.24 (-0.68), SUPN: 13.76 (-0.18)
Georges Gemayel, Ph.D., Joins Supernus Board of Directors
GlobeNewswire - Mon Mar 23, 4:12PM CDT
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Georges Gemayel, Ph.D., a veteran executive with extensive experience in the pharmaceutical industry, will join the company's board of directors.
SUPN: 13.76 (-0.18)
Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 18.52 (-0.03), MDT: 77.61 (-0.89), RARE: 69.65 (+0.75), PFE: 35.27 (-0.09), SUPN: 13.76 (-0.18), NRX: 8.26 (-0.08), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), SVA: 5.10 (unch), BLRX: 2.10 (-0.02), AMPH: 15.25 (-0.04), CHRS: 23.52 (-0.88), JNJ: 101.08 (+0.62), GNVC: 2.82 (+0.01), CYCC: 0.96 (+0.02), AZN: 71.79 (-1.34), DPRX: 12.85 (+0.27), TEVA: 64.41 (+1.16), NBY: 0.63 (unch)
Nasdaq stocks posting largest volume increases
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), ISSI: 18.26 (-0.06), BONT: 7.35 (+0.19), ZGNX: 1.54 (-0.11), SUPN: 13.76 (-0.18), TISA: 3.36 (-0.03), VRA: 13.94 (-0.02), IROQ: 16.64 (+0.14), FCCY: 11.68 (+0.22), REPH: 11.88 (+1.04)
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 12, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
SUPN: 13.76 (-0.18), NMRX: 11.98 (+0.09), EPZM: 20.21 (+0.16), EGRX: 59.30 (-1.62), SLTC: 5.94 (+0.11), ISSI: 18.26 (-0.06), BONT: 7.35 (+0.19), CONN: 30.85 (+0.15), INGN: 37.13 (+0.11), TWOU: 27.86 (-0.91), SCLN: 8.96 (-0.13), CBMG: 29.51 (-1.85)
Citigroup and Intel are big market movers
AP - Thu Mar 12, 4:03PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
ACAD: 38.36 (-0.54), BONT: 7.35 (+0.19), ZGNX: 1.54 (-0.11), SUPN: 13.76 (-0.18), SLXP: 172.96 (+0.15), VRA: 13.94 (-0.02), INTC: 32.08 (-0.27)
Supernus Gains on Solid Q4 Earnings, Encouraging Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 2:46PM CDT
Shares of Supernus Pharmaceuticals, Inc. (SUPN) gained 10.8% after the company reported solid results for the fourth quarter of 2014.
MNK: 122.01 (-2.84), IPXL: 49.55 (-0.53), ACT: 295.41 (-2.95), SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals, Inc. (SUPN) Rises: Stock Up 10.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 12, 8:32AM CDT
Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
AKRX: 55.24 (-0.68), SUPN: 13.76 (-0.18)
Why Supernus Pharmaceuticals, Inc. Stock Spiked
George Budwell, The Motley Fool - Motley Fool - Wed Mar 11, 2:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the specialty drugmaker Supernus...
SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals (SUPN) Stock Is Up Today on Earnings Beat
at The Street - Wed Mar 11, 10:58AM CDT
Supernus Pharmaceuticals (SUPN) is gaining Wednesday after beating analysts' estimates for earnings and revenue in the fourth quarter
SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals' (SUPN) CEO Jack Khattar on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 11, 10:22AM CDT
SUPN: 13.76 (-0.18)
Supernus beats Street 4Q forecasts
Automated Insights - Tue Mar 10, 5:02PM CDT
ROCKVILLE, Md. (AP) _ Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported fourth-quarter net income of $4.4 million, after reporting a loss in the same period a year earlier.
SUPN: 13.76 (-0.18)
Supernus Pharmaceuticals beats by $0.21, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 10, 4:06PM CDT
SUPN: 13.76 (-0.18)
Supernus Announces Fourth Quarter and Full Year 2014 Results
GlobeNewswire - Tue Mar 10, 4:00PM CDT
-- Cash flow positive for the fourth quarter, $5.9 million, and for the full year, $3.2 million.
SUPN: 13.76 (-0.18)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 4:35PM CDT
FCEL: 1.30 (-0.01), SINA: 38.54 (+1.19), NCS: 16.35 (+0.18), ZGNX: 1.54 (-0.11), EOX: 0.61 (-0.02), SUPN: 13.76 (-0.18), HABT: 34.51 (+0.56), ONTY: 1.74 (-0.05), HRZN: 14.30 (+0.06), HTHT: 23.40 (+0.30), SURG: 5.24 (+0.02), WB: 17.20 (+1.31), TCRD: 12.29 (-0.06), MPO: 1.09 (-0.07), PAY: 35.64 (-0.48)
